Business
Revive Therapeutics Announces Results of Annual Shareholder Meeting
TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce the voting results for its annual and special meeting of shareholders (the “Meeting”) that was held on Tuesday, March 18, 2025. At the Meeting, shareholders elected the followin
About this update from Revive Therapeutics Ltd.
[{"type":"image","alt":"Revive Therapeutics Ltd.","displaySize":"","headline":null,"caption":"Revive Therapeutics Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/8660f1b61d5c7f78567e94b161e2d295"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/S_UVHXFUb16rsFeckEL7vA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8660f1b61d5c7f78567e94b161e2d295","width":300,"height":89}},"lazy":false},{"type":"text","content":"TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce the voting results for its annual and special meeting of shareholders (the “Meeting”) that was held on Tuesday, March 18, 2025.","length":456,"tagName":"p"},{"type":"text","content":"At the Meeting, shareholders elected the following nominees to the board of directors:","length":86,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Michael Frank, Chief Executive Officer","length":38,"tagName":"p"}]},{"val":[{"type":"text","content":"Joshua Herman, Independent Director","length":35,"tagName":"p"}]},{"val":[{"type":"text","content":"Andrew Lindzon, Independent Director","length":36,"tagName":"p"}]},{"val":[{"type":"text","content":"William Jackson, Independent Director","length":37,"tagName":"p"}]},{"val":[{"type":"text","content":"Christian Scovenna, Independent Director","length":40,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":186,"olType":false},{"type":"text","content":"Shareholders also approved:","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The appointment of Horizon Assurance LLP, Chartered Professional Accountants, as the auditor of the Company for the ensuing fiscal year","length":135,"tagName":"p"}]},{"val":[{"type":"text","content":"Authorization for the directors to fix the remuneration paid to the auditor","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"A resolution authorizing the continuation of Company’s 10% rolling incentive stock option plan for the ensuing year","length...